Streetbeat News

Price Targets

ARDS

HC Wainwright & Co. analyst Vernon Bernardino has reiterated a 'Buy' rating on Aridis Pharmaceuticals (OTC:ARDS) and maintained a $2 price target.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 12:05 pm

ARQT

Needham analyst Serge Belanger has maintained a 'Buy' rating on Arcutis Biotherapeutics (NASDAQ:ARQT), but lowered the price target from $22 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:59 am

ARQT

HC Wainwright & Co. analyst Serge Belanger maintains a 'Buy' rating on Arcutis Biotherapeutics (NASDAQ:ARQT) but has lowered the price target from $22 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:50 am

ASLN

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on ASLAN Pharma (NASDAQ:ASLN) and maintained a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:48 am

CLSD

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:42 am

KPRX

HC Wainwright & Co. analyst Yi Chen maintains a 'Buy' rating on Kiora Pharmaceuticals (NASDAQ:KPRX) and raises the price target from $2 to $3.5.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:42 am

CDTX

HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Cidara Therapeutics (NASDAQ:CDTX) and maintained a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:40 am

RVNC

HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Revance Therapeutics (NASDAQ:RVNC) but has lowered the price target from $41 to $15.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:38 am

BCRX

Needham analyst Serge Belanger has reiterated a 'Buy' rating on BioCryst Pharma (NASDAQ:BCRX) and maintained a price target of $12.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:34 am

PCRX

HC Wainwright & Co. analyst Oren Livnat maintains a 'Buy' rating on Pacira BioSciences (NASDAQ:PCRX) but lowers the price target from $63 to $57.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:33 am